Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.

Date publication

février 2018

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29205421

Résumé

Biological therapies have improved the care of patients with ulcerative colitis (UC). Tofacitinib, an oral small-molecule Janus kinase inhibitor, is potentially a new treatment option.

Mots clés

Adult, Biological Products, therapeutic use, Biological Therapy, adverse effects, Colitis, Ulcerative, drug therapy, Double-Blind Method, Humans, Network Meta-Analysis, Piperidines, therapeutic use, Pyrimidines, therapeutic use, Pyrroles, therapeutic use, Severity of Illness Index

Référence

Aliment. Pharmacol. Ther.. 2018 02;47(4):454-465